Skip to main content
SpringerLink
Log in

3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells

  • Short Communication
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

The catecholaldehyde hypothesis predicts that monoamine oxidase (MAO) inhibition should slow the progression of Parkinson’s disease, by decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). Inhibiting MAO, however, diverts the fate of cytoplasmic dopamine toward potentially harmful spontaneous oxidation products, indicated by increased 5-S-cysteinyl-dopamine (Cys-DA) levels. 3,4-Dihydroxyphenylethanol (hydroxytyrosol) is an abundant anti-oxidant phenol in constituents of the Mediterranean diet. Whether hydroxytyrosol alters enzymatic or spontaneous oxidation of dopamine has been unknown. Rat pheochromocytoma PC12 cells were incubated with hydroxytyrosol (10 µM, 180 min) alone or with the MAO-A inhibitor clorgyline (1 nM) or the MAO-B inhibitors rasagiline or selegiline (0.5 µM). Hydroxytyrosol decreased levels of DOPAL by 30 % and Cys-DA by 49 % (p < 0.0001 each). Co-incubation with hydroxytyrosol prevented the increases in Cys-DA seen with all 3 MAO inhibitors. Hydroxytyrosol therefore inhibits both enzymatic and spontaneous oxidation of endogenous dopamine and mitigates the increase in spontaneous oxidation during MAO inhibition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Abbreviations

ALDH:

Aldehyde dehydrogenase

DA:

Dopamine

DHPG:

3,4-dihydroxyphenylglycol

DOPAC:

3,4-dihydroxyphenylacetic acid

DOPAL:

3,4-dihydroxyphenylacetaldehyde

DOPET:

3,4-dihydroxyphenylethanol

NE:

Norepinephrine

PD:

Parkinson disease

VMAT:

Vesicular monoamine transporter

References

  1. Burke WJ (2003) 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson’s disease. Curr Drug Targets CNS Neurol Disord 2:143–148

    Article  CAS  PubMed  Google Scholar 

  2. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659–665

    Article  CAS  PubMed  Google Scholar 

  3. Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1812:663–673

    Article  CAS  PubMed  Google Scholar 

  4. Cavalieri EL, Li KM, Balu N, Saeed M, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan EG (2002) Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23:1071–1077

    Article  CAS  PubMed  Google Scholar 

  5. De Marco F, Perluigi M, Marcante ML, Coccia R, Foppoli C, Blarzino C, Rosei MA (2002) Cytotoxicity of dopamine-derived tetrahydroisoquinolines on melanoma cells. Biochem Pharmacol 64:1503–1512

    Article  PubMed  Google Scholar 

  6. Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597–15605

    Article  CAS  PubMed  Google Scholar 

  7. Linsenbardt AJ, Wilken GH, Westfall TC, Macarthur H (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology 30:1030–1035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fornstedt B, Carlsson A (1991) Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Neuropharmacology 30:463–468

    Article  CAS  PubMed  Google Scholar 

  9. Montine TJ, Picklo MJ, Amarnath V, Whetsell WO Jr, Graham DG (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 148:26–33

    Article  CAS  PubMed  Google Scholar 

  10. Spencer JP, Whiteman M, Jenner P, Halliwell B (2002) 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 81:122–129

    Article  CAS  PubMed  Google Scholar 

  11. Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2016) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells. J Pharmacol Exp Ther 356:484–493

    Article  Google Scholar 

  12. Rodriguez-Morato J, Xicota L, Fito M, Farre M, Dierssen M, de la Torre R (2015) Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases. Molecules 20:4655–4680

    Article  CAS  PubMed  Google Scholar 

  13. de la Torre R, Covas MI, Pujadas MA, Fito M, Farre M (2006) Is dopamine behind the health benefits of red wine? Eur J Nutr 45:307–310

    Article  PubMed  Google Scholar 

  14. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C, Visioli F, Distante A, De Caterina R (2003) Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 23:622–629

    Article  CAS  PubMed  Google Scholar 

  15. Lopez de las Hazas MC, Rubio L, Kotronoulas A, de la Torre R, Sola R, Motilva MJ (2015) Dose effect on the uptake and accumulation of hydroxytyrosol and its metabolites in target tissues in rats. Mol Nutr Food Res 59:1395–1399

    Article  CAS  PubMed  Google Scholar 

  16. Gallardo E, Palma-Valdes R, Espartero JL, Santiago M (2014) In vivo striatal measurement of hydroxytyrosol, and its metabolite (homovanillic alcohol), compared with its derivative nitrohydroxytyrosol. Neurosci Lett 579:173–176

    Article  CAS  PubMed  Google Scholar 

  17. Tasset I, Pontes AJ, Hinojosa AJ, de la Torre R, Tunez I (2011) Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington’s disease-like rat model. Nutr Neurosci 14:106–111

    Article  CAS  PubMed  Google Scholar 

  18. Laschinski G, Kittner B, Brautigam M (1986) Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives. Naunyn Schmiedebergs Arch Pharmacol 332:346–350

    Article  CAS  PubMed  Google Scholar 

  19. Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y (2015) Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson’s disease. J Neurochem 133:14–25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2015) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) in PC12 cells. J Pharmacol Exp Ther 356:484–493

    Article  Google Scholar 

Download references

Acknowledgments

The research reported here was supported by the intramural research program of the National Institute of Neurological Disorders and Stroke.

Authors Contribution

David S. Goldstein: Conception and design, data analysis, data interpretation, drafting the article, final approval. Patti Sullivan: Data acquisition, data analysis. Yunden Jinsmaa: Data acquisition, data analysis, conception and design, drafting the article, revising the article. Courtney Holmes: Methods development, new reagents or analytic tools. Irwin J. Kopin: Conception and design, drafting the article, revising the article critically for important intellectual content. Yehonatan Sharabi: Conception and design, data analysis, drafting the article, revising the article critically for important intellectual content.

Author information

Authors and Affiliations

  1. Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH, 9000 Rockville Pike, Bldg. 10 Rm. 5N220, Bethesda, MD, 20892-1620, USA

    David S. Goldstein, Yunden Jinsmaa, Patti Sullivan, Courtney Holmes, Irwin J. Kopin & Yehonatan Sharabi

  2. Sackler Faculty of Medicine, Chaim Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel

    Yehonatan Sharabi

Authors
  1. David S. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yunden Jinsmaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patti Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Courtney Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Irwin J. Kopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yehonatan Sharabi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David S. Goldstein.

Ethics declarations

Conflict of interest

None of the authors has a conflict of interest to report. Dr. Goldstein is Chair of the Education Committee and sits on the Board of Directors of the American Autonomic Society, under an approved Outside Activity. For these services he receives no payment in cash or kind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldstein, D.S., Jinsmaa, Y., Sullivan, P. et al. 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochem Res 41, 2173–2178 (2016). https://doi.org/10.1007/s11064-016-1959-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-016-1959-0

Keywords

Search

Navigation